BioNTech (NASDAQ:BNTX) Price Target Raised to $140.00

BioNTech (NASDAQ:BNTX) had its price target increased by stock analysts at HC Wainwright from $136.00 to $140.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 35.74% from the company’s current price.

Several other research firms have also recently issued reports on BNTX. Bank of America decreased their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Tuesday, October 14th. UBS Group boosted their target price on shares of BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a report on Thursday. Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Finally, Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an “overweight” rating in a research note on Tuesday, August 5th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $134.10.

BioNTech Stock Down 0.2%

Shares of NASDAQ:BNTX opened at $103.14 on Monday. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $23.23 billion, a P/E ratio of -64.46 and a beta of 1.54. BioNTech has a 52-week low of $81.20 and a 52-week high of $129.27. The stock’s fifty day simple moving average is $102.60 and its 200-day simple moving average is $104.97.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period in the prior year, the firm earned $0.81 EPS. The business’s quarterly revenue was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of institutional investors have recently added to or reduced their stakes in BNTX. Baader Bank Aktiengesellschaft boosted its holdings in BioNTech by 6.3% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 151,862 shares of the company’s stock worth $16,032,000 after acquiring an additional 9,040 shares during the period. Shell Asset Management Co. raised its stake in shares of BioNTech by 15.3% during the second quarter. Shell Asset Management Co. now owns 40,610 shares of the company’s stock valued at $4,324,000 after purchasing an additional 5,398 shares during the period. Swedbank AB acquired a new position in shares of BioNTech during the first quarter worth $3,415,000. Millennium Management LLC boosted its stake in shares of BioNTech by 252.5% in the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after purchasing an additional 390,360 shares during the period. Finally, Allianz Asset Management GmbH grew its holdings in BioNTech by 44.3% during the 1st quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company’s stock valued at $10,989,000 after purchasing an additional 37,075 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.